Arrowhead Pharmaceuticals (ARWR) to Release Quarterly Earnings on Monday

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) is anticipated to release its Q2 2025 earnings data after the market closes on Monday, May 12th. Analysts expect Arrowhead Pharmaceuticals to post earnings of ($0.06) per share and revenue of $116.27 million for the quarter.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.97). On average, analysts expect Arrowhead Pharmaceuticals to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Arrowhead Pharmaceuticals Price Performance

ARWR traded down $0.70 on Tuesday, reaching $13.28. The company had a trading volume of 294,651 shares, compared to its average volume of 1,447,697. The company has a market capitalization of $1.82 billion, a P/E ratio of -2.58 and a beta of 0.89. The company has a current ratio of 6.09, a quick ratio of 6.09 and a debt-to-equity ratio of 7.27. The company has a fifty day moving average of $13.85 and a 200-day moving average of $18.15. Arrowhead Pharmaceuticals has a one year low of $9.57 and a one year high of $30.41.

Wall Street Analysts Forecast Growth

ARWR has been the subject of a number of research analyst reports. Royal Bank of Canada restated an "outperform" rating and issued a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. B. Riley reissued a "buy" rating and issued a $38.00 price target (down from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 12th. Finally, Chardan Capital reissued a "buy" rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat, Arrowhead Pharmaceuticals presently has an average rating of "Hold" and an average price target of $41.44.

Insider Activity

In related news, CEO Christopher Richard Anzalone sold 50,800 shares of the firm's stock in a transaction that occurred on Friday, April 11th. The shares were sold at an average price of $11.49, for a total transaction of $583,692.00. Following the completion of the sale, the chief executive officer now directly owns 3,921,255 shares in the company, valued at approximately $45,055,219.95. This trade represents a 1.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders sold 275,880 shares of company stock worth $4,034,037 over the last quarter. Corporate insiders own 4.30% of the company's stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.